SCHEMBL2184252

SCHEMBL2184252

Cn1nc(-c2cccc(Cl)c2)nc2c(=O)n(C)c(=O)nc1-2

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP2 O95551 11/20 0.77
RAF1 P04049 2/20 0.73
MAP2K1 Q02750 2/20 0.73
KDM4E B2RXH2 2/20 0.73
NPC1 O15118 2/20 0.73
LMNA P02545 2/20 0.73
POLB P06746 2/20 0.73
MAPT P10636 2/20 0.73
THRB P10828 2/20 0.73
MAPK1 P28482 2/20 0.73
HTT P42858 2/20 0.73
RECQL P46063 2/20 0.73
RAB9A P51151 2/20 0.73
GALK1 P51570 2/20 0.73
BLM P54132 2/20 0.73
KMT2A Q03164 2/20 0.73
NPSR1 Q6W5P4 2/20 0.73
MEN1 O00255 1/20 0.73
S1PR2 O95136 1/20 0.73
S1PR4 O95977 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2180580 0.84 TDP2 (1.00) TDP2RAF1MAP2K1KDM4ENPC1
SCHEMBL2183740 0.84 TDP2 (1.00) TDP2RAF1MAP2K1KDM4ENPC1
SCHEMBL2183068 0.84 TDP2 (0.74) TDP2RAF1MAP2K1KDM4ENPC1
SCHEMBL15032639 0.82 TDP2 (0.73) TDP2RAF1MAP2K1KDM4ENPC1
SCHEMBL14020030 0.81 TDP2 (0.73) TDP2RAF1MAP2K1KDM4ENPC1
SCHEMBL2182141 0.81 TDP2 (0.71) TDP2RAF1MAP2K1KDM4ENPC1
SCHEMBL2181779 0.79 TDP2 (1.00) TDP2RAF1MAP2K1KDM4ENPC1
SCHEMBL13272626 0.79 TDP2 (0.74) TDP2RAF1MAP2K1KDM4ENPC1
SCHEMBL15032575 0.79 TDP2 (1.00) TDP2RAF1MAP2K1KDM4ENPC1
SCHEMBL3472993 0.78 KDM4C (1.00) TDP2RAF1MAP2K1KDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110166144-A1 Pyrimidotriazinediones and Pyrimidopyrimidinediones and Methods of Using the Same THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166144-A1 Pyrimidotriazinediones and Pyrimidopyrimidinediones and Methods of Using the Same DPYD, TYMP, DHFR TDP2 685/4885RAF1 2577/4885MAP2K1 2120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.